The 21st ESACT conference was held in the beautiful surroundings of the CityWest Hotel resort in Dublin, Ireland. For the first time in ESACT history the number of participants exceeded 900: a sign of the ever increasing importance of this area. The conference commenced on Sunday June 5th with two sets of parallel workshops on the subjects listed below. An additional workshop was held on Monday lunchtime of the conferenceProcess Analytical Technology (PAT), Quality by Design (QbD) and other recent regulatory developments. 2. Innovative media products for the 21st century biopharmaceutical industry. 3. The impact of high titre media feed-streams on monoclonal antibody purification. 4. Advances in genomics and proteomics. 5. Stem Cell Technology: new developments and clinical applications.
Animal cell technology is becoming an increasingly important part of biotechnology and many products are now used in human health care and for veterinary applications. However, there are many times more products actually in the developmental pipelines of the biotechnology industry, including various phases of clinical trials. The Proceedings of the 15th Meeting of the European Society for Animal Cell Technology (Tours, France, September 1997) presents the actual current state as well as New Developments and Applications in Animal Cell Technology for the benefit of society. These Proceedings represent both the current state and applications of animal cell technology and the way the technology is expanding into new areas to give a unique insight into new products and applications for human and animal health care.
The 18th ESACT meeting was celebrated in Granada (Spain) in May 2003, and was entitled "Animal Cell Technology Meets Genomics", in order to reflect that the emerging technologies in the area of genomics, proteomics and other "-omics"-type disciplines will provide key technological assets to increase knowledge and open new horizons in animal cell technology. During the meeting a variety of top-class emerging technologies were presented together with the lastest advances in more mature industrial areas. The meeting was opened by a first session devoted to the understanding of basic cellular mechanisms, and four sessions focused on applied aspects of animal cell technology: Cell-based therapies and gene-based therapies, target discovery and biopharmaceuticals. The Granada Meeting has also seen a special focus on forefront industrial case studies. The spirit and scientific excellence of the 18th ESACT meeting is now reflected in different chapters of the book. The book presents, in form of short papers, a high number of the contributions to the meeting, and has been prepared with the aim to provide a relevant reference of the current research efforts in Animal Cell Technology.
This book is the lasting product, a resource of up-to-date information in the scientific literature for the field of animal cell technology, as it was presented during a pleasant and stimulating meeting in Tylösand, Sweden, in June 2001. The title of the meeting, From Target to Market, indicates the usefulness of Animal Cell Technology during all steps in the pharmaceutical development process. Following the biotech products reaching the market, it shows an upward trend in the contribution of biotech products to total New Molecular Entity output in the nineties, which continued until 1996 when biotech represented 25% of the annual output. Since then the proportion has been decreasing. A perceived hurdle from a market perspective is that a protein per definition is biodegradable and thus requires intravenous, or for some drugs subcutaneous administration. New promising administration technologies such as pulmonary delivery were highlighted at this meeting. The emphasis on project selection prior to entry in the development phase has triggered a portfolio management using more extensive preclinical data before a development decision is taken. Animal cells have become a very important tool in the drug discovery process. The next generation of products will evolve from applications such as gene therapy, novel vaccines, cell therapy, and gene regulation. Animal cell technology has a major role to play in the post-sequence era.
The 19th ESACT meeting was to highlight the novel capabilities of the industry to move the products towards the clinic. It was attended by a wide range of workers in the industry and for many it was their first ESACT meeting. The proceedings here include the short papers adding the knowledge of the previous meetings and provide a reference for the researcher entering, or continuing in the field of Animal Cell Technology.
This book contains, in the form of concise papers of limited length, the proceedings of the 16th ESACT meeting that was held in Lugano, Switzerland, in April 1999. We hope it will become a useful resource of the most up-to-date information in animal cell technology, at least until the next meeting in 2001. Classical approaches for the use of animal cells (for example, production of virus vaccines) remain an important technology. However, it appears that major technological advances and major growth are occurring in other areas. Most importantly, protein production on the basis of recombinant DNA molecules transferred into animal cells appears to be an ever-increasing field of interest and innovation. Increasingly animal cells are being used as substrates for the study of gene activation and repression, and also for the more rapid production of small and moderate quantities of interesting proteins. Tissue engineering, somatic gene/cell therapy, organ-replacement technologies, and cell-based bio-sensors all contribute to a considerable widening of interest and research activity, based on animal cell technology.
This book contains, in the form of concise papers of limited length, the proceedings of the 16th ESACT meeting that was held in Lugano, Switzerland, in April 1999. We hope it will become a useful resource of the most up-to-date information in animal cell technology, at least until the next meeting in 2001. Classical approaches for the use of animal cells (for example, production of virus vaccines) remain an important technology. However, it appears that major technological advances and major growth are occurring in other areas. Most importantly, protein production on the basis of recombinant DNA molecules transferred into animal cells appears to be an ever-increasing field of interest and innovation. Increasingly animal cells are being used as substrates for the study of gene activation and repression, and also for the more rapid production of small and moderate quantities of interesting proteins. Tissue engineering, somatic gene/cell therapy, organ-replacement technologies, and cell-based bio-sensors all contribute to a considerable widening of interest and research activity, based on animal cell technology.
This book is the lasting product, a resource of up-to-date information in the scientific literature for the field of animal cell technology, as it was presented during a pleasant and stimulating meeting in Tylösand, Sweden, in June 2001. The title of the meeting, From Target to Market, indicates the usefulness of Animal Cell Technology during all steps in the pharmaceutical development process. Following the biotech products reaching the market, it shows an upward trend in the contribution of biotech products to total New Molecular Entity output in the nineties, which continued until 1996 when biotech represented 25% of the annual output. Since then the proportion has been decreasing. A perceived hurdle from a market perspective is that a protein per definition is biodegradable and thus requires intravenous, or for some drugs subcutaneous administration. New promising administration technologies such as pulmonary delivery were highlighted at this meeting. The emphasis on project selection prior to entry in the development phase has triggered a portfolio management using more extensive preclinical data before a development decision is taken. Animal cells have become a very important tool in the drug discovery process. The next generation of products will evolve from applications such as gene therapy, novel vaccines, cell therapy, and gene regulation. Animal cell technology has a major role to play in the post-sequence era.
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.